Exagen Inc. provided revenue guidance for the third quarter of 2023. Revenue guidance for the third quarter of 2023 in the range of $10 million to $10.5 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.95 USD | +1.56% | +4.84% | -2.01% |
May. 14 | Cantor Fitzgerald Adjusts Price Target on Exagen to $7 From $5, Maintains Overweight Rating | MT |
May. 13 | Exagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.01% | 33.88M | |
+25.52% | 88.99B | |
-24.52% | 74.82B | |
+0.49% | 25.03B | |
+4.31% | 17.88B | |
-14.25% | 16.43B | |
+2.97% | 15.77B | |
+79.20% | 13.21B | |
+70.11% | 13.08B | |
+40.44% | 12.9B |
- Stock Market
- Equities
- XGN Stock
- News Exagen Inc.
- Exagen Inc. Provides Revenue Guidance for the Third Quarter of 2023